Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 51 | 2025 | 13451 | 2.960 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 34 | 2024 | 5389 | 2.890 |
Why?
|
Acrylamides | 15 | 2024 | 257 | 2.460 |
Why?
|
Protein Kinase Inhibitors | 27 | 2024 | 5696 | 2.080 |
Why?
|
Aniline Compounds | 16 | 2024 | 1075 | 1.660 |
Why?
|
Small Cell Lung Carcinoma | 5 | 2025 | 451 | 1.310 |
Why?
|
Drug Resistance, Neoplasm | 19 | 2024 | 5337 | 1.170 |
Why?
|
Indolizines | 1 | 2023 | 29 | 0.870 |
Why?
|
Mutation | 38 | 2024 | 30198 | 0.860 |
Why?
|
Piperazines | 4 | 2025 | 2549 | 0.770 |
Why?
|
Exons | 7 | 2023 | 2391 | 0.720 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2018 | 422 | 0.620 |
Why?
|
Resorcinols | 1 | 2018 | 41 | 0.610 |
Why?
|
Antineoplastic Agents | 13 | 2021 | 13648 | 0.610 |
Why?
|
Mutagenesis, Insertional | 3 | 2021 | 661 | 0.570 |
Why?
|
Central Nervous System | 1 | 2025 | 1341 | 0.560 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 12 | 2025 | 11868 | 0.560 |
Why?
|
Isoxazoles | 1 | 2018 | 234 | 0.540 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2018 | 228 | 0.540 |
Why?
|
Molecular Targeted Therapy | 8 | 2023 | 2822 | 0.500 |
Why?
|
Biopsy, Fine-Needle | 1 | 2019 | 1133 | 0.440 |
Why?
|
Pyrimidines | 6 | 2024 | 3047 | 0.380 |
Why?
|
Picornaviridae Infections | 1 | 2009 | 97 | 0.290 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2020 | 4044 | 0.280 |
Why?
|
Rhinovirus | 1 | 2009 | 210 | 0.280 |
Why?
|
Adenocarcinoma | 4 | 2018 | 6364 | 0.250 |
Why?
|
Respiratory Sounds | 1 | 2009 | 705 | 0.230 |
Why?
|
Humans | 63 | 2025 | 765968 | 0.210 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2019 | 752 | 0.210 |
Why?
|
Azetidines | 1 | 2024 | 150 | 0.210 |
Why?
|
Carbazoles | 1 | 2024 | 229 | 0.210 |
Why?
|
Early Detection of Cancer | 1 | 2017 | 3236 | 0.200 |
Why?
|
Phthalazines | 1 | 2025 | 397 | 0.190 |
Why?
|
Fibroblast Growth Factor 7 | 1 | 2021 | 59 | 0.190 |
Why?
|
Cytidine Deaminase | 1 | 2023 | 250 | 0.180 |
Why?
|
Respiratory Tract Infections | 1 | 2009 | 1008 | 0.180 |
Why?
|
Maximum Tolerated Dose | 4 | 2024 | 898 | 0.170 |
Why?
|
Hepatocyte Growth Factor | 1 | 2021 | 268 | 0.170 |
Why?
|
Diarrhea | 2 | 2023 | 1316 | 0.160 |
Why?
|
Middle Aged | 25 | 2025 | 223009 | 0.160 |
Why?
|
Aged, 80 and over | 13 | 2025 | 59489 | 0.160 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2021 | 8611 | 0.160 |
Why?
|
Epigenomics | 1 | 2024 | 959 | 0.150 |
Why?
|
Genetic Heterogeneity | 3 | 2020 | 735 | 0.150 |
Why?
|
Disease Progression | 6 | 2021 | 13632 | 0.150 |
Why?
|
Female | 32 | 2025 | 396112 | 0.150 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 260 | 0.150 |
Why?
|
Cell Line, Tumor | 7 | 2019 | 17075 | 0.140 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2019 | 147 | 0.140 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2022 | 1151 | 0.140 |
Why?
|
Aged | 21 | 2025 | 171117 | 0.140 |
Why?
|
Immunoconjugates | 1 | 2024 | 981 | 0.140 |
Why?
|
Indoles | 2 | 2024 | 1839 | 0.130 |
Why?
|
Quinazolinones | 1 | 2018 | 219 | 0.130 |
Why?
|
Eligibility Determination | 1 | 2020 | 423 | 0.130 |
Why?
|
Piperidines | 1 | 2024 | 1664 | 0.130 |
Why?
|
Male | 25 | 2025 | 363698 | 0.130 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 634 | 0.120 |
Why?
|
Neoplasm Metastasis | 3 | 2021 | 4893 | 0.120 |
Why?
|
Carcinoma, Small Cell | 1 | 2017 | 420 | 0.120 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2025 | 9373 | 0.110 |
Why?
|
Gene Amplification | 2 | 2016 | 1091 | 0.110 |
Why?
|
Clinical Trials as Topic | 3 | 2020 | 8041 | 0.110 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2019 | 1608 | 0.110 |
Why?
|
Retreatment | 1 | 2015 | 598 | 0.110 |
Why?
|
Treatment Outcome | 8 | 2025 | 65188 | 0.110 |
Why?
|
Cytoskeletal Proteins | 1 | 2018 | 1325 | 0.100 |
Why?
|
Hemoglobins | 1 | 2019 | 1530 | 0.100 |
Why?
|
Myenteric Plexus | 1 | 2012 | 49 | 0.100 |
Why?
|
Adult | 18 | 2025 | 223044 | 0.100 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2017 | 1624 | 0.100 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 1761 | 0.090 |
Why?
|
Translocation, Genetic | 1 | 2016 | 1394 | 0.090 |
Why?
|
Prognosis | 4 | 2020 | 29922 | 0.090 |
Why?
|
Cohort Studies | 5 | 2021 | 41649 | 0.080 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2019 | 3608 | 0.080 |
Why?
|
DNA, Neoplasm | 1 | 2015 | 1742 | 0.080 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2019 | 2054 | 0.080 |
Why?
|
Quinazolines | 1 | 2016 | 1364 | 0.080 |
Why?
|
Medical Oncology | 1 | 2020 | 2339 | 0.080 |
Why?
|
Mice, Nude | 3 | 2019 | 3618 | 0.080 |
Why?
|
Survival Rate | 2 | 2021 | 12795 | 0.070 |
Why?
|
Patient Selection | 1 | 2020 | 4255 | 0.070 |
Why?
|
Cell Proliferation | 3 | 2020 | 10429 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10383 | 0.070 |
Why?
|
Antibodies, Monoclonal | 1 | 2024 | 9249 | 0.070 |
Why?
|
Molecular Epidemiology | 1 | 2009 | 471 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 4562 | 0.070 |
Why?
|
Base Pair Mismatch | 2 | 2003 | 93 | 0.060 |
Why?
|
Gastrointestinal Tract | 1 | 2012 | 834 | 0.060 |
Why?
|
Radiosurgery | 1 | 2015 | 1328 | 0.060 |
Why?
|
Sulfonamides | 3 | 2020 | 1984 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2021 | 561 | 0.060 |
Why?
|
Terminal Care | 1 | 2016 | 1774 | 0.060 |
Why?
|
Benzamides | 2 | 2021 | 1377 | 0.060 |
Why?
|
Alleles | 1 | 2015 | 6897 | 0.060 |
Why?
|
Microsatellite Repeats | 2 | 2003 | 784 | 0.060 |
Why?
|
RNA, Messenger | 2 | 2016 | 12768 | 0.050 |
Why?
|
Retrospective Studies | 6 | 2024 | 81514 | 0.050 |
Why?
|
Models, Biological | 1 | 2019 | 9443 | 0.050 |
Why?
|
Cell Survival | 3 | 2019 | 5747 | 0.050 |
Why?
|
Apoptosis | 4 | 2019 | 9514 | 0.050 |
Why?
|
Phylogeny | 1 | 2009 | 2832 | 0.050 |
Why?
|
Tumor Cells, Cultured | 2 | 2019 | 6113 | 0.040 |
Why?
|
Sequence Analysis, RNA | 1 | 2009 | 2034 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39193 | 0.040 |
Why?
|
Intestinal Neoplasms | 1 | 2003 | 313 | 0.040 |
Why?
|
Surge Capacity | 1 | 2020 | 48 | 0.040 |
Why?
|
Platinum | 1 | 2021 | 218 | 0.040 |
Why?
|
Radiobiology | 1 | 2020 | 89 | 0.040 |
Why?
|
Nerve Tissue Proteins | 1 | 2012 | 4392 | 0.040 |
Why?
|
Gene Rearrangement | 1 | 2024 | 1144 | 0.040 |
Why?
|
RNA, Small Interfering | 2 | 2019 | 3421 | 0.040 |
Why?
|
Genomic Instability | 1 | 2023 | 718 | 0.040 |
Why?
|
Triazines | 1 | 2021 | 307 | 0.040 |
Why?
|
Data Interpretation, Statistical | 1 | 2009 | 2686 | 0.040 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2003 | 587 | 0.040 |
Why?
|
Sequence Deletion | 1 | 2023 | 1495 | 0.040 |
Why?
|
Diphenylamine | 1 | 2018 | 49 | 0.040 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2023 | 604 | 0.040 |
Why?
|
Lung | 1 | 2017 | 10033 | 0.040 |
Why?
|
Cell Cycle | 2 | 2017 | 2920 | 0.040 |
Why?
|
Cell Growth Processes | 1 | 2019 | 381 | 0.040 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2018 | 99 | 0.040 |
Why?
|
Keratin-8 | 1 | 2017 | 11 | 0.040 |
Why?
|
rac1 GTP-Binding Protein | 1 | 2019 | 246 | 0.040 |
Why?
|
Keratin-18 | 1 | 2017 | 37 | 0.040 |
Why?
|
Biopsy | 2 | 2021 | 6763 | 0.040 |
Why?
|
Neoplasm Staging | 2 | 2024 | 11206 | 0.040 |
Why?
|
Prospective Studies | 3 | 2021 | 54802 | 0.040 |
Why?
|
Lactams | 1 | 2017 | 159 | 0.030 |
Why?
|
Pyrimidinones | 1 | 2019 | 384 | 0.030 |
Why?
|
Brain Neoplasms | 1 | 2018 | 9071 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2020 | 2266 | 0.030 |
Why?
|
Pyrazoles | 2 | 2017 | 2033 | 0.030 |
Why?
|
Mice | 5 | 2024 | 81819 | 0.030 |
Why?
|
Lactams, Macrocyclic | 1 | 2017 | 318 | 0.030 |
Why?
|
Pyridines | 2 | 2017 | 2888 | 0.030 |
Why?
|
North America | 1 | 2018 | 1285 | 0.030 |
Why?
|
Animals | 7 | 2024 | 168764 | 0.030 |
Why?
|
Imidazoles | 1 | 2021 | 1162 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10729 | 0.030 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2024 | 2844 | 0.030 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 904 | 0.030 |
Why?
|
Time Factors | 3 | 2021 | 40065 | 0.030 |
Why?
|
Pyridones | 1 | 2019 | 816 | 0.030 |
Why?
|
Aminopyridines | 1 | 2017 | 576 | 0.030 |
Why?
|
Gene Expression | 2 | 2017 | 7584 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2021 | 1995 | 0.030 |
Why?
|
Physician's Role | 1 | 2020 | 927 | 0.030 |
Why?
|
Codon | 1 | 2015 | 595 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2017 | 2476 | 0.030 |
Why?
|
Mice, SCID | 1 | 2018 | 2630 | 0.030 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2018 | 1333 | 0.030 |
Why?
|
Tumor Burden | 1 | 2018 | 1885 | 0.030 |
Why?
|
Up-Regulation | 1 | 2021 | 4137 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2021 | 3537 | 0.020 |
Why?
|
High-Throughput Screening Assays | 1 | 2017 | 938 | 0.020 |
Why?
|
Gene Dosage | 1 | 2016 | 1216 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2019 | 2140 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2024 | 3819 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2019 | 2394 | 0.020 |
Why?
|
Amino Acid Substitution | 1 | 2015 | 1740 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 1106 | 0.020 |
Why?
|
DNA Methylation | 1 | 2024 | 4424 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6499 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2020 | 5302 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2019 | 2132 | 0.020 |
Why?
|
DNA Damage | 1 | 2019 | 2457 | 0.020 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2018 | 1892 | 0.020 |
Why?
|
Patient Care Team | 1 | 2020 | 2517 | 0.020 |
Why?
|
Mushroom Poisoning | 1 | 1968 | 5 | 0.020 |
Why?
|
Immunohistochemistry | 3 | 2012 | 11022 | 0.020 |
Why?
|
Hospitalization | 1 | 2009 | 10808 | 0.020 |
Why?
|
Neoplasms | 1 | 2017 | 22340 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2018 | 18293 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2020 | 3564 | 0.020 |
Why?
|
Blotting, Western | 1 | 2016 | 5020 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2021 | 3946 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2018 | 2942 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2016 | 4108 | 0.020 |
Why?
|
Infant | 1 | 2009 | 36386 | 0.020 |
Why?
|
Hyperglycemia | 1 | 2015 | 1393 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2017 | 5786 | 0.020 |
Why?
|
Signal Transduction | 2 | 2021 | 23601 | 0.020 |
Why?
|
Immunotherapy | 1 | 2021 | 4752 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2016 | 6832 | 0.020 |
Why?
|
Research Design | 1 | 2020 | 6209 | 0.010 |
Why?
|
Young Adult | 2 | 2021 | 59889 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2018 | 14448 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2003 | 6942 | 0.010 |
Why?
|
Adolescent | 3 | 2021 | 88835 | 0.010 |
Why?
|
MutS Homolog 2 Protein | 1 | 2003 | 200 | 0.010 |
Why?
|
Swine | 1 | 2012 | 5988 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2018 | 6547 | 0.010 |
Why?
|
Genotype | 1 | 2016 | 13024 | 0.010 |
Why?
|
Neoplasm Proteins | 2 | 2003 | 3596 | 0.010 |
Why?
|
Phenotype | 1 | 2018 | 16721 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 18071 | 0.010 |
Why?
|
Adenosine Triphosphate | 1 | 2003 | 1999 | 0.010 |
Why?
|
Rats | 1 | 2012 | 23707 | 0.010 |
Why?
|
Age of Onset | 1 | 2003 | 3344 | 0.010 |
Why?
|
Quality of Life | 1 | 2016 | 13462 | 0.010 |
Why?
|
DNA Repair | 1 | 2003 | 2048 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20659 | 0.010 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2003 | 2900 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2003 | 4520 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2003 | 4913 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2003 | 5783 | 0.000 |
Why?
|
Age Factors | 1 | 2003 | 18380 | 0.000 |
Why?
|
DNA-Binding Proteins | 1 | 2003 | 9601 | 0.000 |
Why?
|